BG Medicine (OTCMKTS: BGMD) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.
Volatility & Risk
BG Medicine has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.
This table compares BG Medicine and Miragen Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BG Medicine||$1.57 million||0.29||-$5.30 million||N/A||N/A|
|Miragen Therapeutics||$3.34 million||51.63||-$12.67 million||($8.93)||-0.87|
BG Medicine has higher earnings, but lower revenue than Miragen Therapeutics.
This table compares BG Medicine and Miragen Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
22.6% of Miragen Therapeutics shares are owned by institutional investors. 6.5% of BG Medicine shares are owned by insiders. Comparatively, 44.4% of Miragen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of recent recommendations and price targets for BG Medicine and Miragen Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Miragen Therapeutics has a consensus target price of $24.00, indicating a potential upside of 210.48%. Given Miragen Therapeutics’ higher probable upside, analysts clearly believe Miragen Therapeutics is more favorable than BG Medicine.
Miragen Therapeutics beats BG Medicine on 7 of the 11 factors compared between the two stocks.
BG Medicine Company Profile
BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners’ automated platforms. The Company’s CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Miragen Therapeutics Company Profile
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Receive News & Ratings for BG Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BG Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.